Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Ardiani A, Farsaci B, Rogers CJ, Protter A, Guo Z, King TH, Apelian D, Hodge JW.

Clin Cancer Res. 2013 Nov 15;19(22):6205-18. doi: 10.1158/1078-0432.CCR-13-1026.

2.
3.

Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.

Bennett LL, Ingason A.

Ann Pharmacother. 2014 Apr;48(4):530-7. doi: 10.1177/1060028013518899. Review.

PMID:
24458946
4.

Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.

Shiota M, Yokomizo A, Takeuchi A, Imada K, Kashiwagi E, Song Y, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

Clin Cancer Res. 2014 Feb 15;20(4):951-61. doi: 10.1158/1078-0432.CCR-13-1809.

5.

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.

Clin Cancer Res. 2014 Jun 15;20(12):3198-210. doi: 10.1158/1078-0432.CCR-13-3296. Erratum in: Clin Cancer Res. 2017 Jan 1;23 (1):323.

6.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

7.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015.

PMID:
24837187
8.
9.

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S, Sternberg CN.

Drug Des Devel Ther. 2015 Jun 29;9:3325-39. doi: 10.2147/DDDT.S69433. Review.

10.
11.

Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.

Graff JN, Gordon MJ, Beer TM.

Expert Opin Pharmacother. 2015 Apr;16(5):749-54. doi: 10.1517/14656566.2015.1016911. Review.

PMID:
25687355
12.

Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.

Schalken J, Fitzpatrick JM.

BJU Int. 2016 Feb;117(2):215-25. doi: 10.1111/bju.13123. Review.

13.

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI.

Eur Urol. 2015 Nov;68(5):795-801. doi: 10.1016/j.eururo.2015.01.026.

14.

Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.

Shiota M, Yokomizo A, Takeuchi A, Itsumi M, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

Prostate. 2014 Jun;74(9):959-69. doi: 10.1002/pros.22813.

PMID:
24740858
15.

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.

van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CM, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur Urol. 2015 Jun;67(6):981-5. doi: 10.1016/j.eururo.2014.11.033.

PMID:
25484141
16.

Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients.

Dhingra R, Sharma T, Singh S, Sharma S, Tomar P, Malhotra M, Bhardwaj TR.

Mini Rev Med Chem. 2013 Aug;13(10):1475-86. Review.

PMID:
23701654
17.

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.

Mol Pharmacol. 2015 Jun;87(6):1006-12. doi: 10.1124/mol.114.097477.

18.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674.

PMID:
23765603
19.

Enzalutamide: looking back at its preclinical discovery.

Ha YS, Kim IY.

Expert Opin Drug Discov. 2014 Jul;9(7):837-45. doi: 10.1517/17460441.2014.918947. Review.

PMID:
24820058
20.

The evolving role of enzalutamide on the treatment of prostate cancer.

Nadal R, Bellmunt J.

Future Oncol. 2016 Mar;12(5):607-16. doi: 10.2217/fon.15.351. Review.

PMID:
26839021
Items per page

Supplemental Content

Support Center